CN Patent

CN119654152A — 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂

Assigned to AstraZeneca AB · Expires 2025-03-18 · 1y expired

What this patent protects

本公开涉及在治疗癌症中使用的表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)，其中该EGFR TKI与c‑MET抑制剂组合施用。

USPTO Abstract

本公开涉及在治疗癌症中使用的表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)，其中该EGFR TKI与c‑MET抑制剂组合施用。

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

Patent Metadata

Patent number: CN119654152A
Jurisdiction: CN
Classification: —
Expires: 2025-03-18
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.